Psychedelic Medicine Sector

[gfp927z]

>>> PharmaTher Inc. (PHRRF), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals such as ketamine and psilocybin, for FDA approval to treat mental health, neurological and pain disorders. <<<

https://www.pharmather.com/


Transdermal delivery of psychedelic pharmaceuticals


Fabio Chianelli, Chairman and Chief Executive Officer

Mr. Chianelli has over 15 years of experience with specialty life sciences companies. He was the Founder and President of Revive Therapeutics Ltd. (CSE: RVV) between 2012 and 2019. From January 2000 to January 2012, Mr. Chianelli held senior roles in investor relations, business development, and marketing and sales with Generex Biotechnology Corporation. Mr. Chianelli received his Bachelor of Commerce from Ryerson University.
?

Dr. Beverly J. Incledon – Director

Dr. Incledon is the Executive Vice President, Research & Development of Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Toronto-based Highland Therapeutics Inc. Dr. Incledon has over 20 years of pharmaceutical industry experience encompassing drug discovery, product development, pre-approval inspections, development quality, project management, method/technology transfer, process improvement, manufacturing troubleshooting, new development facility start-up, and research on novel drug delivery technology. Dr. Incledon was a Post-Doctoral Fellow at Cornell University and obtained his PhD degree in Biophysics and Bachelor of Science (Honors) in Applied Biochemistry with a Minor in Biomedical Technology from the University of Guelph.
?

Christian Scovenna – Director

Mr. Scovenna is a highly experienced C-Suite Executive with over 13 years of capital market experience working with both private and public microcap companies in Canada. He has held numerous directorships with publicly-traded resource, pharmaceutical and cannabis companies and has experience structuring deals and acquisitions and raising capital. In his previous engagement with Mojave Jane Brands Inc. (formerly, High Hampton Holdings Corp.) (CSE: JANE), he was instrumental in building the company as one of the original founders and was a key member of the management team as interim CEO and Senior VP Corporate Finance while also serving on the board as a director. Mr. Scovenna currently serves as Director for Revive Therapeutics (CSE: RVV.C), Pasofino Gold Limited (formerly Enforcer Gold Corp.) (TSXV: VEIN) and Tevano Payment Systems as VP Of Corporate Development.


Carlo Sansalone – Director

Mr. Sansalone is President at Sanscon Construction Ltd. He is on the Board of Directors at Revive Therapeutics Ltd. (CSE: RVV.C). Mr. Sansalone received his undergraduate degree from Ryerson University

<<<